Gofrit ON, Meirovitz A, Frank S, et al. - In view of a wide variation in the reported results of trimodal treatment (TMT) in muscle‐invasive bladder cancer, researchers sought to characterize the profile of ideal candidates for this approach. They retrospectively analyzed 105 patients (median age 78 years) with T2‐4aN0M0 bladder cancer who underwent TMT from 2000 to 2019. Mean radiotherapy dose of 62 Gy (SD 8.4) was reported. After a median follow‐up of 29 months, recurrence developed in 53 patients (50.5%) and death was reported for 70 patients (67.7%). They identified tumor diameter to be the most significant prognostic parameter for overall, disease‐specific and recurrence‐free survivals. The risk of disease‐specific mortality increased by 1.57 for every 1 cm increase in tumor diameter. Following were significant predictors of overall survival but not of disease‐specific or recurrence‐free survival: age, cisplatin eligibility and the Charlson Comorbidity Index. Patient profiles had accurate predictive value for response to TMT. An excellent disease‐specific survival rate is achieved with TMT in cisplatin‐eligible patients with a tumor diameter ≤ 3 cm. TMT resulted in unacceptably poor treatment outcomes in patients with a tumor diameter > 5 cm.